Drug
Envafolimab clinical trials
Also written KN035.
- studies test it
- 66
- open now
- 44
- in phase 3
- 3
- first study started
- 2017
Keep track of what changes. Save the envafolimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
66 studies that test it; most in 2022 (19)
| Year | Studies |
|---|---|
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 4 |
| 2022 | 19 |
| 2023 | 15 |
| 2024 | 11 |
| 2025 | 6 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 58
- Phase 3
- 3
- Phase 4
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 54
3D Medicines (Sichuan) Co., Ltd. (8) · Sun Yat-sen University (5) · Sir Run Run Shaw Hospital (3) · Ascletis Pharmaceuticals Co., Ltd. (2) · The First People's Hospital of Lianyungang (2) · Fudan University (2) · Tianjin Medical University Cancer Institute and Hospital (2) · Peking Union Medical College Hospital (2)
Often tested with
Tested in the same studies.
Endostar protein (8) · Gemcitabine (5) · Lenvatinib (5) · Cisplatin (3) · Albumin-Bound Paclitaxel (3) · Paclitaxel (3) · Oxaliplatin (2) · Irinotecan (2)
Studies
Open first, then newest update. How each study uses envafolimab is read from its arms, and is right about nine times in ten.
Testing it · 66
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)RecruitingPhase 2The Second Affiliated Hospital of Chongqing Medical UniversityNCT07852091Written as Sintilimab/Envafolimab
- Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal AdenocarcinomaRecruitingPhase 3Sir Run Run Shaw HospitalNCT05752136Written as Envafolimab
- SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLCNot yet recruitingPhase 2The First People's Hospital of LianyungangNCT07818304Written as Envafolimab
- A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver SpreadNot yet recruitingPhase 2Fudan UniversityNCT07256223Written as Envafolimab+Lenvatinib
- ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus InfectionRecruitingPhase 4The Second Affiliated Hospital of Chongqing Medical UniversityNCT07573943Written as Anti-PD-L1 antibody (ASC22)
- Study on the Combined Treatment of Hepatocellular Carcinoma With Envafolimab, Suvemcitug and HAIC ConversionNot yet recruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT07738055Written as Envafolimab: 400mg, subcutaneous injection Suvemcitug: 2mg/kg, intravenous injection HAIC: Oxaliplatin 85mg/m² + 5-FU 2400-3200mg/m², continuous infusion, every 3 weeks
- ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRCRecruitingPhase 2Beijing HospitalNCT06321081Written as irinotecan, cetuximab, envafolimab
- Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard TreatmentRecruitingPhase 2Jian LiNCT07559864Written as Regorafenib + Envafolimab
- A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor PatientsRecruitingPhase 1Kangabio AUSTRALIA LTD PTYNCT07260305Written as Envafolimab
- Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerRecruitingPhase 23D Medicines (Sichuan) Co., Ltd.NCT05112991Written as Envafolimab+Lenvatinib
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingPhase 1/23D Medicines (Sichuan) Co., Ltd.NCT05024214Written as Lenvatinib + Envafolimab
- ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid TumorsRecruitingPhase 23D Medicines (Sichuan) Co., Ltd.NCT04891198Written as Envafolimab
- Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT05959356Written as Cetuximab + Envafolimab + mFOLFOXIRI
- Envafolimab Combined With Axitinib as First-Line Treatment for Patients With Advanced Renal Cell CarcinomaNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07159191Written as Envafolimab Injection, Axitinib Tablets
- Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma PatientsNot yet recruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07142863Written as Envafolimab and neoadjuvant chemotherapy
- Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract CancerNot yet recruitingPhase 2Tongji HospitalNCT07003815Written as Envafolimab + Gemcitabine + Cisplatin + Simvastatin
- A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)Not yet recruitingPhase 2/3Sun Yat-sen UniversityNCT06959693Written as Envafolimab
- Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric CancerRecruitingPhase 2First Affiliated Hospital of Fujian Medical UniversityNCT06791083Written as Envafolimab
- Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung CancerRecruitingPhase 2Guangdong Provincial People's HospitalNCT06734182Written as Envafolimab injections+intravenous Disitamab Vedotin+carboplatin
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingPhase 2Peking University Shenzhen HospitalNCT06692491Written as Envafolimab
See all 66 studies that test envafolimab →
Given in every arm · 6 — envafolimab is usual care beside what is tested
- Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and CarboplatinRecruitingPhase 2Shanghai Chest HospitalNCT06698965Written as Immunotherapy （Envafolimab）
- Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal CancerRecruitingPhase 2Sun Yat-sen UniversityNCT06014372Written as Envafolimab
- RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2Not yet recruitingPhase 2Jiangsu Cancer Institute & HospitalNCT05417230Written as Envafolimab
- ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or MyxofibrosarcomaActive, not recruitingPhase 2Tracon Pharmaceuticals Inc.NCT04480502Written as Envafolimab
- A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid TumorsTerminatedPhase 2Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05148195Written as Envofolimab
- YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic SarcomaActive, not recruitingPhase 1/2Tracon Pharmaceuticals Inc.NCT05448820Written as Envafolimab
As the comparator · 1 — what is tested is compared with envafolimab
Codes
What other systems call envafolimab · ClinicalTrials.gg INT001692
- MeSH (NLM) C000718749envafolimabOne source NLM
- UNII (FDA) ES1M06M6QHENVAFOLIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q123499516envafolimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C129714EnvafolimabOne source FDA
- DrugBank DB15769One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000718749 | envafolimab | One source NLM |
| UNII (FDA) | ES1M06M6QH | ENVAFOLIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123499516 | envafolimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C129714 | Envafolimab | One source FDA |
| DrugBank | DB15769 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.